About Kerendia®▼ (finerenone)
Kerendia (finerenone) is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
The FIDELIO-DKD trial showed there was a sustained reduction in CKD progression* with kerendia compared to placebo.
Overall frequency of adverse events was similar in the two groups. The most frequent adverse reaction with kerendia was hyperkalaemia (14.0%)
NICE recommends Kerendia®, the first and only UK licensed non-steroidal MRA, as an add-on to standard of care for stage 3 and 4 CKD (with albuminuria) associated with T2D
Kerendia® slows CKD progression in T2D and can significantly delay progression of renal disease (vs. placebo)
Diabetic kidney disease is progressive and irreversible; act now with Kerendia® to significantly reduce the risk of renal & CV events for your patient (vs. placebo)
*defined as 1st occurrence of composite of onset of kidney failure or sustained decrease of eGFR≥ 40% from baseline over at least 4 weeks or death due to renal causes. Kidney failure defined as initiation of dialysis for ≥90days or kidney transplantation or eGFR <15ml/min/1.73m2 over ≥4weeks
CKD=chronic kidney disease; MOD=mechanism of disease; MOA=mechanism of action; T2D=type 2 diabetes.
PP-KER-GB-0903 | March 2026
